Brief: Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026
09/06/2025 13:00
June 9 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS RECEIVES INITIAL PROCEEDS FROM FDA ORPHAN PRODUCTS GRANT TO SUPPORT PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS PALVELLA THERAPEUTICS INC - TOP-LINE DATA FROM SELVA EXPECTED IN Q1 2026 PALVELLA THERAPEUTICS INC - UP TO $2.6 MILLION IN NON-DILUTIVE FUNDING ANTICIPATED OVER GRANT PERIOD PALVELLA THERAPEUTICS INC - SELVA TRIAL ON TRACK TO REPORT RESULTS IN Q1 2026 Source text: ID:nGNX4Mr30 Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs